Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Valens GroWorks Quarterly Results Are Worth Processing
https://www.google.com/amp/s/smallcappower.com/news/market-news/valens-groworks-quarterly-results-processing/amp/
Yeah MADD, certainly played a role especially vape gate
Sonofabitch Hippd, you better be listening to your own predictions and buying LABS , VFF , etc and flipping for big $$$$. Screw that agraflora stock. Bang on with those calls.....UNFORTUNATELY!!!
Oh, I am only holding VGW and LABS. I never sell for a loss on these. I am patient holding and will only swing some for gains and buy back on dips. They always bounce just gotta ride the waves sometimes.......
It’s just hard to feel confident in this sector right now(ie, TRUL , VGW earnings we’re great) but the shorts are killing it and are in control... we as longs lose and that’s the sad truth for now
Keep an eye on them this sector is bipolar right now
lol, : )
FIND US ONLINE
MediPharm Labs Enters New Beverages and Culinary Lifestyle Market Through Cannabis Concentrate Supply Partnership with Tea and Edibles Company Olli Brands Inc.
FOR IMMEDIATE RELEASE
TORONTO, October 16, 2019 (GLOBE NEWSWIRE): MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has signed a private label cannabis concentrate supply agreement with Olli Brands Inc. (“Olli”), an innovative leader in the creation and food-grade manufacturing of premium, smoke-free cannabis-infused edibles and teas.
Under the 18-month supply agreement, MediPharm will provide high-quality cannabis distillate and crude to Olli upon its commercial licensing. Olli will utilize MediPharm’s products to infuse its line of curated edibles created by Olli’s renowned Michelin-trained chef Adrian Niman of The Food Dudes and its family of teas designed by renowned tea specialist Richard Guzauskas, head of blend development for a major North American tea retailer and founder of Leaves Pure Tea. Olli currently holds a research licence under the Cannabis Act and is awaiting final approval for its standard processing licence prior to commercializing its line of edible and tea-based products.
This agreement demonstrates the demand for MediPharm Labs’ cannabis extracts for use as input products in the manufacturing of the second wave of Canadian recreational cannabis products (“Cannabis 2.0”) expected to hit shelves at the end of this year.
“The culinary lifestyle market is the next frontier for MediPharm Labs and we can’t think of a better way to enter this important new category than through this exciting collaboration with Olli and its team of experts,” said Patrick McCutcheon, Chief Executive Officer of MediPharm Labs. “According to Statistics Canada, quality and safety are leading purchase considerations for Canadians when selecting their cannabis products. Based on the rigorous approach we take to product design, development, testing and precision manufacturing, our B2B customers can trust that our input products used for cannabis beverages and edibles will set the industry standard for premium quality, reliability and taste.”
“Olli is thrilled to be partnering with the unparalleled leader in pharmaceutical-like cannabis extraction,” said Sarah Gillin, Co-Founder and Chief Operating Officer of Olli. “MediPharm Labs' commitment to excellence aligns perfectly with Olli's goal to be the leader in premier curated cannabis infused teas and edibles. We couldn't be more excited to be moving forward with this partnership.”
MediPharm Labs will supply cannabis concentrates to Olli from its purpose built 70,000 square foot GMP-designed production facility in Barrie, Ontario. The facility features ISO-standard clean rooms, critical environment laboratories, commercial-grade distillation, chromatography R&D and supercritical CO2 primary extraction lines, each assigned to specific customer batches. The facility recently received Organic Certification from Pro-Cert Organic Systems Ltd., one of North America’s leading certifiers of organic products. This certification assists in extending MediPharm Labs’ capabilities to include the production of bulk wholesale organic extracts and oil for use as ingredients in finished cannabis concentrate derivatives such as edibles, extracts, topicals and oil products.
A Trusted Supply Chain
MediPharm Labs places a premium on production quality and the integrity of its supply chain. The Company utilizes standardized operating procedures and meticulous record keeping ensuring repeatability of manufacturing in every batch, which leads to consistent and trusted products for its customers to utilize in their manufacturing processes. To achieve this, MediPharm Labs employs highly experienced experts across a number of core disciplines.
“MediPharm Labs is ready to help Olli give Canadians the low-dose, curated cannabis infused edibles and beverages they can trust,” said Mr. McCutcheon. “We are delighted to be part of this category-defining collaboration and view this supply agreement as demonstrating the suitability of our cannabis concentrates for these Cannabis 2.0 product categories.”
About Olli
Olli is a Toronto, Ontario-based cannabis-infused product manufacturer working with best-in-class suppliers using quality ingredients to offer premium-grade cannabis products. Founded by friends John B. Aird and Sarah Gillin in 2017, out of an idea to enjoy smoke-free cannabis products, Olli was created by friends, for friends, to provide a thoughtfully curated, health-minded, enjoyable and safe way to consume cannabis goods. Olli’s product line includes quality edibles curated by award-winning and Michelin-starred restaurant-trained chef Adrian Niman of the Food Dudes, and cannabis-infused teas developed by famed tea specialist Richard Guzauskas. Olli’s products will be manufactured at Olli’s facility located in Etobicoke, Ontario. Once legalized, Olli products will be sold across provincially licenced retailers in Canada.
All information contained in this press release with respect to Olli and its future plans was supplied by Olli for inclusion herein.
ABOUT MEDIPHARM LABS
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing an organically certified, Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed commercial exports to Australia and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.
FOR FURTHER INFORMATION, PLEASE CONTACT:
MediPharm Labs
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, supply of distillate and crude to Olli upon Olli’s commercial licensing, manufacture by Olli and other third-parties of Cannabis 2.0 products using MediPharm’s inputs, production capabilities of MediPharm related to organic product, the legality of new cannabis-derived products and timing thereof, the completion of the Australian facility and the processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Facebook ? Twitter ? Instagram ? LinkedIn ? YouTube ?
MediPharm Labs
151 John Street
Barrie, Ontario L4N 2L1 Canada
Unsubscribe bflogwm@mac.com
Update Profile | About Constant Contact
Sent by investors@medipharmlabs.com
CPG PARTNERSHIP: @MediPharmLabs Enters New Beverages and Culinary Lifestyle Market Through Cannabis Concentrate Supply Partnership with Tea and Edibles Company Olli Brands
Yep, all extractors should benefit going forward
Boom!! Just the beginning here.... let the shorts go in the a.m. and buckle in for the long ride : )
Actually in Chicago on October 22-23
Thanks guys.... one big MED HEAD family : )
Missed that....thought they were in U.K. tomorrow????
VGW cancelled the plans of growing their own....they are learning from MEDIF but behind....great company in long run
I reread it , so 190%+ increase in price it says so YES usd dollars!
lol, likewise!
Interesting you ask, I was debating this also....I’m gonna assume being that the article is talking MEDIF/ US ticker it’s in usd dollars .... so $8.50 US
lol, deswag!! : )
MediPharm Labs (OTCMKTS:MEDIF) Given a $8.50 Price Target by Canaccord Genuity Analysts
https://www.google.com/amp/s/rivertonroll.com/news/2019/10/12/medipharm-labs-otcmktsmedif-given-a-8-50-price-target-at-canaccord-genuity.html/amp
MEDIPHARM $LABS: 2019-2020 Shareholder Updates :
[color=red][/color]
- Q1/2019 - revenue of 22M
- Q2/2019 - revenue of 31.42M
- Q3/2019 - November 12, 2019
Pre market
- Capital Structure:
Fully diluted shares (as of May 10, 2019): 140M + ~potentially 15M from its latest bought deal.. So approximately ~155M
- Business model: wholesale(Private labelling + white labelling)/tolling
Sales/tolling agreements with - Supreme, Terrascend, Emerald Health, Indiva, JWCA, Cronos Group, Canopy Growth, & undisclosed licensed producer
More agreements to be announced
- Current capacity of 150,000kg - expected to complete expansion to 250,000kg by end of Q2/19 (hopefully to be announced soon this week)
- Cashed up
- has closed a credit agreement (the “Credit Facility”) with a top 5 Canadian Schedule 1 bank (the “Bank”) for an aggregate $38.7 million.
recently closed a $75M bought deal @$5.55 option to purchase additional shares up to $86M
Signed $20M in debt with schedule 1 Bank
Total cash $100M+
- Up list to TSX
- Global reach
Facility under construction in Australia (Expected to be completed in H2 2019) - 75,000 KG capacity expected for H2 2019 (November)
https://www.newcannabisventures.com/canadian-extraction-leader-medipharm-labs-announces-first-supply-partnerships-for-australian-subsidiary/
Facility in Australia will be the HUB to export extracts/finished products into Asia Pacific
Facility in Canada will be the HUB to export extracts/finished products into Europe
Awaiting EU GMP certification - expected H2 2019 ( in order to ship to the EU)
Recently completed its first export shipment into Australia to AusCann Group holdings (https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aLABS-2776284&symbol=LABS®ion=C) ;
- Building towards a pharmceutical company
Formed a Science Advisory Committee group;expert scientist, researchers, and medical professionals
Focused on Pharma-grade cannabis oil and concentrates
More information here: https://www.civilized.life/articles/how-medipharm-is-preparing-for-the-future-of-cannabis/ ;
- Slides:
https://d1io3yog0oux5.cloudfront.net/_0e3791d75c2e44476440cbd2788c3a11/medipharmlabs/db/357/2889/pdf/MediPharm+Labs+-+October+2019.pdf
https://stockdaymedia.com/cannabis/medipharm-labs-and-cronos-group-enter-private-label-contract-manufacturing-agreement/
https://m.benzinga.com/article/14480625?utm_referrer=https%3A%2F%2Fwww.google.com%2F&utm_source=https%3A%2F%2Fwww.google.com%2F
Hope your timing is right too.. Stocks are soaring cannabis sector is down, Stocks are down cannabis sector down......go figure
Agree
Well this Sector is beat down and not sure when we recover, what a sad fact. Even the few good ones will fall to this negativity.....see you back here in about 16 months, lol
I believe you thnx
What a ass backwards psycho sector this is! lol , I’ll wait it out with my LABS shares
Thumbs up deswag!
We are on the same page! : )
Yep, I feel some big plans in the work for $LABS ....growth!!!!
MediPharm Labs Closes New $38.7 Million Up-sized Credit Facility with a Top 5 Canadian Schedule 1 Bank to Support Growth
I know you do....GL my friend!!!!
Thought this would make you happy: )
3 Marijuana Stocks That Should Uplist to the Nasdaq or NYSE Next
$LABS, $MEDIF
https://www.google.com/amp/s/www.fool.com/amp/investing/2019/10/09/3-marijuana-stocks-that-should-uplist-to-the-nasda.aspx
WTF IS RIGHT!!!
You know when you throw these charts on LABS , VGW don’t matter good company like VFF and LABS ,,,,,shorts in control right now
@ValensGroWorks will issue its third-quarter financial results, for the period ended August 31, 2019 on Tuesday, October 15, 2019 after markets close
Hey gang no evidence to back this up but ; FYI, Whispers around that Health Canada issued a request for SKUs on vapes / scheduled a call for 10/17. Unconfirmed but read-through would imply no vape ban? Again DK if true but..... could be great news